Table 1.
Baseline characteristics of patients.
| Overall Population (n = 95) | Aerobic (n = 40) | Concurrent (n = 55) | |
|---|---|---|---|
| Age, y | 63.1 ± 6 | 62.6 ± 6 | 63.7 ± 2 |
| BMI, Kg/m2 | 27.6 | 27.8 ± 2 | 27.2 ± 3 |
| NYHA class II/III | 2.6 ± 0.5 | 2.8 ± 1.1 | 2.4 ± 0.8 |
| Resting HR, bpm | 68.7 ± 13.4 | 66.9 ± 11.1 | 69.0 ± 17.2 |
| Systolic BP, mmHg | 123.3 ± 38.5 | 123.3 ± 38.5 | 123.3 ± 38.5 |
| Diastolic BP, mmHg | 83.5 ± 11.8 | 85.6 ± 16.3 | 82.0 ± 14.1 |
| Previous CABG/PCI | 43/68 | 19/30 | 24/38 |
| Comorbidities | |||
| Hypertension | 72 | 30 | 42 |
| Diabetes | 31 | 12 | 19 |
| COPD | 16 | 6 | 10 |
| Carotid artery disease | 28 | 11 | 17 |
| History of smoke/active smoker | 71/9 | 30/5 | 41/4 |
| Echocardiography | |||
| LVDD, mm | 58.1 ± 5 | 58.6 ± 7 | 57.3 ± 8 |
| LVSD, mm | 45.9 ± 4 | 45 ± 5 | 46 ± 5 |
| Ejection fraction, % | 42.0 ± 9 | 42.6 ± 9 | 41.8 ± 12 |
| TAPSE, mm | 21.3 ± 4 | 20.7 ± 7 | 22.0 ± 5 |
| Treatment | |||
| Beta-blockers | 83 | 35 | 48 |
| ACE-i/ARBs | 76 | 32 | 44 |
| Diuretics | 47 | 20 | 27 |
| Aldosteron-antagonists | 67 | 28 | 39 |
| Statins | 71 | 30 | 41 |
| Sacubitril/valsartan | 12 | 4 | 8 |
| Ivabradine | 7 | 2 | 5 |
BMI, body mass index; CABG, Coronary artery bypass graft; PCI, percutaneous coronary intervention; LVDD, left ventricular diastolic diameter; LVSD, left ventricular systolic diameter; TAPSE, tricuspid annulus plane systolic excursion.